Evidence map›Paper›PMID 40610535›Full record

ArticleScientific reports2025

Pancreatic cancer organoids derived from EUS-guided fine needle aspiration specimens can be used to predict chemotherapy resistance.

Soshi Oyama, Akiko Matsuda, Ryoko Murakami, Yasuharu Kakizaki, Tetsuya Ishizawa, Toshikazu Kobayashi, Hitomi Nakamura, Yoshihito Nawa, Yu Otaki, Yamato Nagata and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Soshi OyamaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Akiko MatsudaDepartment of Gastroenterology Faculty of Medicine, Yamagata University, Yamagata, Japan. m.akiko@med.id.yamagata-u.ac.jp.
Ryoko MurakamiDivision of Multi-omics Research, Yamagata University Well-being Institute, Yamagata, Japan.
Yasuharu KakizakiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Tetsuya IshizawaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Toshikazu KobayashiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Hitomi NakamuraDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Yoshihito NawaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Yu OtakiDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Yamato NagataDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Soichiro HonmaDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Naohiko MakinoDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Hidenori SatoDivision of Multi-omics Research, Yamagata University Well-being Institute, Yamagata, Japan.
Yoshiyuki UenoDepartment of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Although chemotherapy has become increasingly important in recent years, there are no practical markers to predict therapeutic efficacy. Here, we have aimed to identify novel markers that predict resistance to chemotherapy drugs using patient-derived organoids (PDOs) of PDAC. PDOs were established using endoscopic ultrasound - guided fine needle aspiration (EUS-FNA) specimens. Drug sensitivity tests were performed on 15 PDOs and the correlation between drug sensitivity and transcriptome analysis were evaluated. BARD1 and RAD50 have been identified as genes associated with gemcitabine resistance. Additionally, SLC25A10 and MAP3K9 were identified as genes associated with gemcitabine + paclitaxel resistance.PDOs derived from EUS-FNA specimens can be used to assess individual drug resistance and to identify predictive factors for chemotherapy resistance.

Indexed as

Carcinoma, Pancreatic DuctalDrug Resistance, NeoplasmOrganoidsPancreatic NeoplasmsAgedDeoxycytidineEndoscopic Ultrasound-Guided Fine Needle AspirationFemaleGemcitabineHumansMaleMiddle AgedPaclitaxelDeoxycytidineGemcitabinePaclitaxelBiomarkersDrug screeningOrganoidsPancreatic cancer

Identifiers

PMID40610535
PMCPMC12229655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.